Geron Corp

Research Geron Corp (GERN) on Bullrun: market cap USD 995.83M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 995.83M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 183.88M-USD 83.50M-USD 111.09M97.4%-0.13USD 77.56MUSD 119.55MUSD 225.87M
FY2024USD 76.99M-USD 174.57M-USD 219.30M98.4%-0.27USD 79.02MUSD 118.48MUSD 280.32M
FY2023USD 237.00K-USD 184.13M-USD 168.57Mn/a-0.32USD 70.02MUSD 81.94MUSD 247.95M
FY2022USD 596.00K-USD 141.90M-USD 127.81Mn/a-0.37USD 56.85MUSD 51.16MUSD 80.00M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 995.83Mn/an/an/a
20252025-12-31USD 844.61Mn/an/an/a
20242024-12-31USD 2.15Bn/an/an/a
20232023-12-29USD 1.15Bn/an/an/a
20222022-12-30USD 922.59Mn/an/an/a
20212021-12-31USD 394.95Mn/an/an/a

About Geron Corp

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis;

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Geron Corp's market cap?

Geron Corp's market capitalization is USD 995.83M.

What does Geron Corp do?

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology.